Liver function in children with human immunodeficiency virus infection before and after 6 months of highly active antiretroviral therapy

被引:0
|
作者
Sapulete, Eva Jacomina Jemima [1 ]
Putra, I. Gusti Ngurah Sanjaya [1 ]
Wati, Ketut Dewi Kumara [1 ]
Santoso, Hendra [1 ]
Witarini, Komang Ayu [1 ]
Karyana, I. Putu Gede [1 ]
Nesa, Ni Nyoman Metriani [1 ]
机构
[1] Univ Udayana, Sanglah Hosp, Med Sch, Dept Child Hlth, Jalan Pulau Nias, Denpasar 80114, Bali, Indonesia
关键词
liver function; pediatric; human immunodeficiency virus; antiretroviral;
D O I
10.14238/pi58.4.2018.159-64
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background highly active antiretroviral therapy (HAART) has resulted in dramatic decreases in morbidity and improved survival rate in human immunodeficiency virus (HIV)-infected patients. Although the risk of morbidity has decreased, it has been replaced by other long-term complications, such as hepatotoxicity. Hepatotoxicity is often reflected in biochemical abnormalities of liver function, such as elevated levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and aspartate aminotransferase-to-platelet ratio index (APRI). Objective To compare liver function spectrum (AST, ALT, and APRI) in HIV-infected children before and after at least 6 months of HAART. Methods This observational study (before and after) was conducted in pediatric patients with HIV infection who received HAART for at least 6 months at Sanglah Hospital, Denpasar. Data were collected from medical records. Results Forty-nine patients were observed in this study. The mean AST, ALT, and APRI levels before HAART were higher than after at least 6 months of HAART: Anti-tuberculosis treatment and fluconazole therapy were not confounding factors for AST, ALT, and APRI. Conclusion Liver function spectrum enzyme levels of AST, ALT, and APRI are improved after at least 6 months of HAART.
引用
收藏
页码:159 / 164
页数:6
相关论文
共 50 条
  • [41] Epidural lipomatosis causing new debilitating back pain in a patient with human immunodeficiency virus on highly active antiretroviral therapy
    Billings, F.
    Hoyt, M. R.
    INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA, 2012, 21 (04) : 367 - 370
  • [42] Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active Antiretroviral therapy in patients with human immunodeficiency virus
    Nguyen, Scan I.
    Eaton, Susan A.
    Bain, Amy M.
    Rahman, Anita P.
    Payne, Kenna D.
    Bedimo, Roger
    Herrington, Jon D.
    Maclayton, Darego O.
    Rodriguez-Barradas, Maria C.
    Busti, Anthony J.
    PHARMACOTHERAPY, 2008, 28 (03): : 323 - 330
  • [43] Different profiles of immune reconstitution in children and adults with HIV-infection after highly active antiretroviral therapy
    Salvador Resino
    Elena Seoane
    Alicia Pérez
    Ezequiel Ruiz-Mateos
    Manuel Leal
    Maria Á Muñoz-Fernández
    BMC Infectious Diseases, 6
  • [44] Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy
    Bonnet, F
    Lewden, C
    May, T
    Heripret, L
    Jougla, E
    Bevilacqua, S
    Costagliola, D
    Salmon, D
    Chêne, G
    Morlat, P
    CANCER, 2004, 101 (02) : 317 - 324
  • [45] Oral Candida flora from Brazilian human immunodeficiency virus-infected patients in the highly active antiretroviral therapy era
    Melo, NR
    Taguchi, H
    Jorge, J
    Pedro, RJ
    Almeida, O
    Fukushima, K
    Nishimura, K
    Miyaji, M
    MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2004, 99 (04): : 425 - 431
  • [46] Obstetric and newborn infant outcomes in human immunodeficiency virus-infected women who receive highly active antiretroviral therapy
    Haeri, Sina
    Shauer, Marla
    Dale, Monica
    Leslie, Jennie
    Baker, Arthur M.
    Saddlemire, Stephanie
    Boggess, Kim
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2009, 201 (03) : 315.e1 - 315.e5
  • [47] Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease
    Hoffmann, C
    Chow, KU
    Wolf, E
    Faetkenheuer, G
    Stellbrink, HJ
    van Lunzen, J
    Jaeger, H
    Stoehr, A
    Plettenberg, A
    Wasmuth, JC
    Rockstroh, J
    Mosthaf, F
    Horst, HA
    Brodt, HR
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (04) : 455 - 462
  • [48] Effect of anthropometric and sociodemographic variables on physical activity levels of people living with human immunodeficiency virus/acquired immunodeficiency syndrome on highly active antiretroviral therapy
    Anikpe, Jane Nwanneka
    Chukwu, Aroh Joseph
    Edem, Ekom Ndifreke
    Elahmar, Adel A. E.
    Sinha, Sohini
    Arome, David
    TZU CHI MEDICAL JOURNAL, 2023, 35 (02): : 200 - 204
  • [49] Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy
    Rahman, Anita P.
    Eaton, Susan A.
    Nguyen, Sean T.
    Bain, Amy M.
    Payne, Kenna D.
    Bedimo, Roger
    Busti, Anthony J.
    PHARMACOTHERAPY, 2008, 28 (07): : 913 - 919
  • [50] The active human immunodeficiency virus reservoir during antiretroviral therapy: emerging players in viral persistence
    Astorga-Gamaza, Antonio
    Buzon, Maria J.
    CURRENT OPINION IN HIV AND AIDS, 2021, 16 (04) : 193 - 199